Clinical Trials And Drug DevelopmentPositive Top-line data for Phase 2 clinical trial for AL001 was reported, indicating potential advancements in Alzheimer’s treatment.
Regulatory MilestonesThe company's programs in post-traumatic stress disorder, major depressive disorder, and bipolar disorder received the green light from the FDA, signaling a positive regulatory environment.
Stock Rating And ValuationCurrent valuation is considered attractive, maintaining a BUY rating with a significant upside potential.